Janux Therapeutics Inc [JANX] stock prices are up 8.09% to $44.65 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 5.03% over the last week, with a monthly amount drifted -17.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on December 03, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $70 from $63. Previously, BTIG Research reaffirmed its Buy rating on December 03, 2024, and elevated its price target to $100. On November 22, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $79 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $69 on October 24, 2024. Stifel initiated its recommendation with a Buy and recommended $70 as its price target on September 06, 2024. Scotiabank started tracking with a Sector Perform rating for this stock on May 30, 2024, and assigned it a price target of $47. In a note dated March 21, 2024, BTIG Research initiated an Buy rating and provided a target price of $62 on this stock.
The stock price of Janux Therapeutics Inc [JANX] has been fluctuating between $7.79 and $71.71 over the past year. Currently, Wall Street analysts expect the stock to reach $70.25 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $44.65 at the most recent close of the market. An investor can expect a potential return of 57.33% based on the average JANX price forecast.
Analyzing the JANX fundamentals
The Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 13.05M for trailing twelve months, representing a drop of -82.56%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -6.59%, Pretax Profit Margin comes in at -4.64%, and Net Profit Margin reading is -4.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.1 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.86 points at the first support level, and at 39.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.62, and for the 2nd resistance point, it is at 48.58.
Ratios To Look Out For
It’s worth pointing out that Janux Therapeutics Inc [NASDAQ:JANX]’s Current Ratio is 38.80. Further, the Quick Ratio stands at 38.80, while the Cash Ratio is 1.56. Considering the valuation of this stock, the price to sales ratio is 197.76, the price to book ratio is 3.56.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on Feb 03 ’25 when 3334.0 shares were sold. Officer, ANDREW MEYER completed a deal on Feb 03 ’25 to buy 3334.0 shares. Meanwhile, President and CEO Campbell David Alan sold 5000.0 shares on Jan 07 ’25.
